The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Open accessAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes coronavirus disease 2019 (COVID-19) and was declared a pandemic by the World Health Organization (WHO) on 11 March 2020. Herd or community immunity has been proposed as a strategy to protect the vulnerable, and can be established through immunity from past infection or vaccination. Whether SARS-CoV-2 infection results in the development of a reservoir of resilient memory cells is under investigation. Vaccines have been developed at an unprecedented rate and 7 408 870 760 vaccine doses have been administered worldwide. Recently emerged SARS-CoV-2 variants are more transmissible with a reduced sensitivity to immune mechanisms. This is due to the presence of amino acid substitutions in the spike protein, which confer a selective advantage. The emergence of variants therefore poses a risk for vaccine effectiveness and long-term immunity, and it is crucial therefore to determine the effectiveness of vaccines against currently circulating variants. Here we review both SARS-CoV-2-induced host immune activation and vaccine-induced immune responses, highlighting the responses of immune memory cells that are key indicators of host immunity. We further discuss how variants emerge and the currently circulating variants of concern (VOC), with particular focus on implications for vaccine effectiveness. Finally, we describe new antibody treatments and future vaccine approaches that will be important as we navigate through the COVID-19 pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–221 of 221
Ford, C. T., Jacob Machado, D., & Janies, D. A. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.830202 · Cited by 52
Bao, C., Tao, X., Cui, W., Hao, Y., Zheng, S., Yi, B., Pan, T., Young, K. H., & Qian, W. (2021) · Experimental Hematology & Oncology · doi:10.1186/s40164-021-00199-1 · Cited by 47
Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concernPreprint
Jongeneelen, M. A. C., Kaszás, K., Veldman, D., Huizingh, J., van der Vlugt, R., Schouten, T. G., Zuijdgeest, D., Uil, T. G., Roey, G. V., Guimerà, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.01.450707 · Cited by 45
Emergence of multiple SARS-CoV-2 mutations in an immunocompromised hostPreprint
Khatamzas, E., Rehn, A., Muenchhoff, M., Hellmuth, J. C., Gaitzsch, E., Weiglein, T., Georgi, E., Scherer, C., Stecher, S. S., Weigert, O., et al. (2021) · medRxiv · doi:10.1101/2021.01.10.20248871 · Cited by 44
Castillo‐Olivares, J., Wells, D. A., Ferrari, M., Chan, A. C. Y., Smith, P., Nadesalingam, A., Paloniemi, M., Carnell, G., Ohlendorf, L., Cantoni, D. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748291 · Cited by 44
Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses
O’Connell, P., & Aldhamen, Y. A. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1802974 · Cited by 37
Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions
Silva, P. J. S., Sagastizábal, C. A., Nonato, L. G., Struchiner, C. J., & Pereira, T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104640118 · Cited by 37
Structural Analysis of the SARS-CoV-2 Omicron Variant Proteins
Yang, Q., Syed, A. A. S., Fahira, A., & Shi, Y. (2021) · Research · doi:10.34133/2021/9769586 · Cited by 36
Kaneko, N., Kuo, H.-H., Boucau, J., Farmer, J. R., Allard‐Chamard, H., Mahajan, V. S., Trocha, A. K., Lefteri, K., Osborn, M., Bals, J., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3652322 · Cited by 32
Spatio-temporal dynamics of intra-host variability in SARS-CoV-2 genomes
Pathak, A. K., Mishra, G. P., Uppili, B., Walia, S., Fatihi, S., Abbas, T., Banu, S., Ghosh, A., Kanampalliwar, A. M., Jha, A., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1297 · Cited by 31
Weber, S., Ramirez, C. M., Weiser, B., Burger, H., & Doerfler, W. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114062 · Cited by 30
Fernández, J., Bruneau, N., Fasce, R., Martín, H. S., Balanda, M., Bustos, P., Ulloa, S., Mora, J., & Ramírez, E., V (2021) · Journal of Medical Virology · doi:10.1002/jmv.27310 · Cited by 27
Rodrigues, P. R. S., Alrubayyi, A., Pring, E., Bart, V. M. T., Jones, R. E., Coveney, C. R., Lu, F., Tellier, M., Maleki-Toyserkani, S., Richter, F. C., et al. (2020) · Oxford Open Immunology · doi:10.1093/oxfimm/iqaa005 · Cited by 26
Genomic Evolution of SARS-CoV-2 Virus in Immunocompromised Patient, Ireland
Lynch, M., Macori, G., Fanning, S., O’Regan, E., Hunt, E., O’Callaghan, D. S., McCullagh, B. N., Jennings, C., & Fortune, A. (2021) · Emerging infectious diseases · doi:10.3201/eid2709.211159 · Cited by 26
Khedar, R. S., Mittal, K., Ambaliya, H. C., Mathur, A. V., Gupta, J. B., Sharma, K. K., Singh, Y., Sharma, G., Gupta, A., Bhargava, V., et al. (2021) · medRxiv · doi:10.1101/2021.09.03.21263091 · Cited by 25
Payne, R., Longet, S., Austin, J. A., Skelly, D., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S. E., Al‐Taei, S., Moore, S. C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3891065 · Cited by 24
Abid, M. A., Nunley, L., & Abid, M. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01294 · Cited by 22
Ongoing recombination in SARS-CoV-2 revealed through genealogical reconstructionPreprint
Ignatieva, A., Hein, J., & Jenkins, P. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.21.427579 · Cited by 18
Lauro, R., Irrera, N., Eid, A. H., & Bitto, A. (2021) · Pathogens · doi:10.3390/pathogens10040476 · Cited by 12
Rare COVID reactions might hold key to variant-proof vaccines
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-00722-8 · Cited by 8
Heterologous vaccination strategy for containing COVID-19 pandemicPreprint
Lin, A., Liu, J., Ma, X., Zhao, F., Yu, B., He, J., Shen, M., Huang, L., Tang, H., Jiang, E., et al. (2021) · medRxiv · doi:10.1101/2021.05.17.21257134 · Cited by 6
Metadata
- Authors
- Mistry, P., Barmania, F., Mellet, J., Peta, K., Strydom, A., Viljoen, I. M., James, W., Gordon, S., & Pepper, M. S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-03
- Volume
- 12
- Pages
- 809244-809244
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4206545113
- Cited by
- 299
- References
- 221
- FWCI
- 33.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.